Enanta Pharmaceuticals

Enanta Pharmaceuticals

Biotechnology Research

Watertown, MA 9,564 followers

Our vision is to transform the lives of patients with curative therapies.

About us

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for virology and immunology indications. Enanta’s research and development programs are currently focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU) and the company has previously advanced clinical-stage compounds for SARS-CoV-2 (COVID-19) and chronic hepatitis B virus (HBV) infection. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.

Website
http://www.enanta.com
Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
Watertown, MA
Type
Public Company
Specialties
Virology and Immunology

Locations

Employees at Enanta Pharmaceuticals

Updates

Similar pages

Browse jobs

Funding

Enanta Pharmaceuticals 8 total rounds

Last Round

Post IPO equity

US$ 9.2M

See more info on crunchbase